Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (881-890 of 934) with videos related to

Pageof 94
Sort By:
JAMA Cardiology|May 19, 2021
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI RegistryAdam N Berman, David W Biery, Curtis Ginder, et al.
European Journal of Preventive Cardiology|October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic DiseaseAndre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology|September 11, 2024
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHFAnkeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Population Health Management|December 4, 2024
Identifying Patients with Heart Failure Eligible for Guideline-Directed Medical TherapySamantha Subramaniam, Shahzad Hassan, Ozan Unlu, et al.
Obesity (Silver Spring, Md.)|December 19, 2024
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care systemJohn W Ostrominski, Kavishwar B Wagholikar, Kelly Olsson, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
JAMA|April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Pageof 94

Showing results (881-890 of 934) with videos related to

Sort By:
Pageof 94
JAMA Cardiology|May 19, 2021
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI RegistryAdam N Berman, David W Biery, Curtis Ginder, et al.
European Journal of Preventive Cardiology|October 28, 2025
Polygenic Risk Score for Coronary Artery Disease Across the Spectrum of Atherosclerotic DiseaseAndre Zimerman, Frederick K Kamanu, Giorgio E M Melloni, et al.
Journal of the American College of Cardiology|September 11, 2024
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHFAnkeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Population Health Management|December 4, 2024
Identifying Patients with Heart Failure Eligible for Guideline-Directed Medical TherapySamantha Subramaniam, Shahzad Hassan, Ozan Unlu, et al.
Obesity (Silver Spring, Md.)|December 19, 2024
Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care systemJohn W Ostrominski, Kavishwar B Wagholikar, Kelly Olsson, et al.
Journal of the American Heart Association|September 2, 2017
Self-Reported Health and Outcomes in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Emil Hagström, Claes Held, et al.
JAMA|April 5, 2008
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Pageof 94